CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines

Meta stock rose about 1.5% on Wednesday as broader markets moved higher ahead of a pivotal interest rate decision from the Federal Reserve, while fresh bullish calls from analysts added to the positive sentiment around the social media giant. The shares have gained about 20% over the past month, extending a recovery that has been supported by new artificial intelligence products, improved monetization prospects and the removal of a major legal overhang.

Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.

AngloGold Ashanti is advancing two Nevada projects, targeting long-term gold production growth as Arthur Gold moves toward a full feasibility study.

RGLD's 2026 revenues surge 128% y/y as new contributions from Kansanshi and acquired assets strengthen its diversified precious metals portfolio.

Amazon Now's $1B annualized sales mark and rapid expansion in India raise questions about whether its quick-commerce momentum can last.

Speculative drone stocks are extending a month-long drift lower Wednesday morning, and the shape of the session is doing most of the talking. The REX Drone ETF (NASDAQ:DRNZ) is up 0.3% to $20.37, holding slightly positive on the day.

Dell Technologies shares DELL rose more than 5% in trading on Wednesday as Goldman Sachs raised its forecast for the global server market, highlighting continued expectations for strong growth in artificial intelligence infrastructure. Goldman Sachs now expects the overall server market to reach $1.5 trillion by 2030, representing a compound annual growth rate (CAGR) of 39% from 2025 to 2030.

EzyTrace Integrates Fertilizer Stock Tracking, Logistics Visibility and Modern Farming Intelligence EzyTrace Integrates Fertilizer Stock Tracking, Logistics Visibility and Modern Farming Intelligence

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

PEP faces softer North America demand, margin pressure and higher costs, while its discounted valuation reflects cautious growth expectations.
